← back to search

Yukiko Onishi

The Institute of Medical Science, Asahi Life Foundation · JP
Area of research
Endocrinology, Diabetes and Metabolism · Molecular Biology
Research interest
Research interests include Diabetes Treatment and Management, Diabetes, Cardiovascular Risks, and Lipoproteins, Metabolism, Diabetes, and Cancer, and Diabetes Management and Research.
h-index
42
citations
6,144
works
130
NIH funding
primary concept
Medicine
email

Recent publications

Sex Differences in Fasting Glucose Levels among Non-diabetic Japanese: Men Exhibit Higher Levels Than Women.
2026cited by 0position: contributordoi
Evaluation of the effectiveness and safety of ONO-2910 for the treatment of diabetic polyneuropathy: An early Phase IIa, multicenter, randomized, placebo-controlled, double-blind study in Japanese patients.
2026cited by 0position: contributordoi
Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes
New England Journal of Medicine 2025cited by 64position: contributordoi
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes.
2025cited by 32position: contributordoi
Long-term safety and efficacy of imeglimin in Japanese individuals with type 2 diabetes and chronic kidney disease: A 52-week postmarketing clinical study (TWINKLE).
2025cited by 1position: contributordoi
Thirty-Year Trends in the Prevalence and Severity of Diabetic Retinopathy at the First Visit in Patients with Untreated Type 2 Diabetes Mellitus.
2025cited by 0position: contributordoi
Once-weekly insulin efsitora alfa versus once-daily insulin degludec in adults with type 1 diabetes (QWINT-5): a phase 3 randomised non-inferiority trial.
2024cited by 29position: contributordoi
Efficacy of Save Medical Corporation (SMC)-01, a Smartphone App Designed to Support Type 2 Diabetes Self-Management Based on Established Guidelines: Randomized Controlled Trial.
2024cited by 4position: contributordoi
Metabolic Abnormalities Following Tirzepatide Monotherapy in Japanese Patients with Type 2 Diabetes: A Phase 3 SURPASS J-mono Post Hoc Analysis.
2024cited by 3position: contributordoi
Association of glucagon-like peptide-1 receptor agonist treatment with gastric residue in an esophagogastroduodenoscopy.
2023cited by 105position: contributordoi
Association of self-stigma with glycated hemoglobin: A single-center, cross-sectional study of adults with type 1 diabetes in Japan.
2023cited by 5position: contributordoi
Cardiovascular disease prevalence in adults with type 2 diabetes in Japan: results from the Japanese centers in the CAPTURE study.
2023cited by 3position: contributordoi
Use of diabetes medications in adults with T2D and CVD in Japan: secondary analysis of the CAPTURE study.
2023cited by 0position: contributordoi
Efficacy of Save Medical Corporation (SMC)–01, a Smartphone App Designed to Support Type 2 Diabetes Self-Management Based on Established Guidelines: Randomized Controlled Trial (Preprint)
2023cited by 0position: contributordoi
Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial.
2022cited by 414position: contributordoi
Diabetes management by either telemedicine or clinic visit improved glycemic control during the coronavirus disease 2019 pandemic state of emergency in Japan.
2022cited by 20position: contributordoi
Substitution of telemedicine for clinic visit during the COVID-19 pandemic of 2020: Comparison of telemedicine and clinic visit.
2022cited by 10position: contributordoi
Association of insulin treatment with gastric residue during an esophagogastroduodenoscopy.
2022cited by 4position: contributordoi
Clinical features and sulfonylurea usage among outpatients with diabetes aged ≥90 years in an urban diabetes clinic in Tokyo.
2022cited by 0position: contributordoi
Synergistic association of the copper/zinc ratio under inflammatory conditions with diabetic kidney disease in patients with type 2 diabetes: The Asahi Diabetes Complications Study
Journal of Diabetes Investigation 2021cited by 34position: contributordoi
Associations between diabetes duration and self-stigma development in Japanese people with type 2 diabetes: a secondary analysis of cross-sectional data.
2021cited by 12position: contributordoi
How self-stigma affects patient activation in persons with type 2 diabetes: a cross-sectional study.
2020cited by 43position: contributordoi
Effect of postprandial hyperglycemia at clinic visits on the incidence of retinopathy in patients with type 2 diabetes: An analysis using real-world long-term follow-up data.
2020cited by 11position: contributordoi
Once-Weekly Dulaglutide with Insulin Therapy for Type 2 Diabetes: Efficacy and Safety Results from a Phase 4, Randomized, Placebo-Controlled Study.
2020cited by 9position: contributordoi
Comparison of twenty indices of insulin sensitivity in predicting type 2 diabetes in Japanese Americans: The Japanese American Community Diabetes Study.
2020cited by 3position: contributordoi
Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial.
2019cited by 476position: contributordoi
Efficacy, Safety, and Tolerability of Oral Semaglutide Versus Placebo Added to Insulin With or Without Metformin in Patients With Type 2 Diabetes: The PIONEER 8 Trial
Diabetes Care 2019cited by 276position: middledoi
Efficacy, Safety, and Tolerability of Oral Semaglutide Versus Placebo Added to Insulin With or Without Metformin in Patients With Type 2 Diabetes: The PIONEER 8 Trial.
2019cited by 197position: contributordoi
Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes (the DEPICT-2 Study): 24-Week Results From a Randomized Controlled Trial
Diabetes Care 2018cited by 251position: middledoi
Optimum BMI Cut Points to Screen Asian Americans for Type 2 Diabetes
Diabetes Care 2015cited by 139position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

· 12 papers (2021–2026)Toshiko Takao · Jikei University School of Medicine4 papers (2021–2023)Masaomi Nangaku · Saitama Medical University2 papers (2023–2024)Ryo Saito · University of Tokyo Hospital2 papers (2023–2024) · 2 papers (2023–2024)Shunpei Enomoto · University of Tokyo Hospital2 papers (2023–2024)Kayo Waki · Diabetes Australia2 papers (2023–2024)Tetsuya Kubota · The Institute of Medical Science, Asahi Life Foundation2 papers (2023–2025)Toshimasa Yamauchi · Toranomon Hospital2 papers (2023–2024)Satoshi Nozoe · 2 papers (2023–2024)Sakurako Hamagami · 2 papers (2023–2024)Nicholas Leung · 2 papers (2023–2024)Takashi Kadowaki · Oasis Hospital2 papers (2020–2021)Marguerite J. McNeely · University of Cape Town1 papers (2015–2015)Bernard Zinman · Lunenfeld-Tanenbaum Research Institute1 papers (2019–2019) · 1 papers (2015–2015) · 1 papers (2015–2015)Hiroki Yamazaki · Shimane University1 papers (2021–2021)Sheldon Tobe · Marcus (United States)1 papers (2019–2019)Salvatore De Cosmo · Casa Sollievo della Sofferenza1 papers (2019–2019)